Study Evaluating the Safety and Efficacy of Bapineuzumab in Alzheimer Disease Patients

• Status: Terminated
• Trial end date: 2012-11-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a study to evaluate the efficacy and safety of multiple doses of bapineuzumab in patients with mild to moderate Alzheimer Disease. Patients will receive either bapineuzumab or placebo. Each patient's participation will last approximately 1.5 years.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer

Criteria

Inclusion Criteria:

• Diagnosis of probable AD, with MMSE score of 16-26, and brain MRI consistent with the diagnosis of AD

• Concurrent use of cholinesterase inhibitor or memantine allowed, if stable.

• Caregiver will participate and be able to attend clinic visits with patient.

Exclusion Criteria:

• Significant neurological disease other than AD, or a major psychiatric disorder

• Contraindication to undergo brain MRI (e.g., pacemaker, CSF shunt, or foreign metal objects in the body)

• Woman of childbearing potential